肉毒毒素在可行走痉挛型脑瘫儿童多模式治疗中的作用:成本效果试验的深入评估
本文基于Space Bop成本效果试验,该试验发现对于接受综合康复的可行走痉挛型脑瘫儿童,腿部肌肉注射肉毒毒素(BoNT-A)在多模式干预的一个独立治疗周期中无附加价值。作者讨论试验设计、结果解读及推广中的关键问题与障碍,强调认识这些因素对康复研究和成果转化的重要性。
要点
- Space Bop试验显示BoNT-A在综合康复中无附加价值,但该反直觉结果遭质疑。
- 文章讨论5个影响结果接受度的问题,涉及研究设计、临床经验、治疗目标等。
- 认识这些障碍有助于康复研究的开展及研究结果的传播与实施。
核心结论
- 尽管Space Bop研究结果明确,但多个因素阻碍了结果的接受。
研究设计与样本
- 本文为讨论性文章,基于Space Bop成本效果试验,讨论5个关键问题。
主要发现
- 对于接受综合康复的可行走痉挛型脑瘫儿童,BoNT-A在一个独立治疗周期中无附加价值。
临床怎么用
- 在康复研究和结果推广中应认识并关注影响结果接受度的相关因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A cost-effectiveness trial (the Space Bop study) on the added value of botulinum toxin injections (BoNT-A) in the leg muscles, as part of a multimodal intervention for ambulatory children with spastic cerebral palsy in the context of a single distinct cycle of care was performed recently by our group. For a broad set of effect outcomes, we found that BoNT-A had no added value if children received comprehensive rehabilitation. However, this counterintuitive finding was met with scepticism. OBJECTIVE: Since several noteworthy facts and experiences were recorded during the course of the trial and the dissemination phase, the aim of this paper was to describe and discuss some crucial aspects of, and barriers to, the Space Bop study, related to context and perspective, design and results, as well as publication and implementation. METHODS: This paper discusses 5 issues: (i) the design, interpretation and presentation of previous research; (ii) the role of one's own clinical experience and interpretation; (iii) the aims of (BoNT-A) treatment; (iv) conflict of interest, role of industry, and the role of history; (v) optimal treatment modalities and dose-response relationships. CONCLUSION: Despite the unambiguous findings from the Space Bop study, several factors hindered acceptance of the results. Awareness of these factors is important when performing rehabilitation research and disseminating and implementing research findings.
引用
- Bussmann JBJ, Pangalila RF, Stam HJ, et al. The role of botulinum toxin in multimodal treatment of spasticity in ambulatory children with spastic Cerebral Palsy: extensive evaluation of a cost-effectiveness trial. J Rehabil Med. 2020. PMID: 32301499. doi:10.2340/16501977-2680
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。